MEDTR.E — Meditera Tibbi Malzeme Sanayi ve Ticaret AS Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Market Cap
TRY3.23bn
Enterprise Value
TRY2.90bn
Revenue
TRY2.87bn

Annual income statement for Meditera Tibbi Malzeme Sanayi ve Ticaret AS, fiscal year end - December 31st, TRY millions except per share, conversion factor applied.

	2021 December 31st	R2022 December 31st	R2023 December 31st	R2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	376	1,596	2,097	2,741	2,874
Cost of Revenue
Gross Profit	166	681	929	1,083	876
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	296	1,213	1,705	2,442	2,779
Operating Profit	80	383	392	300	94.6
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	202	196	80.3	95	-16.1
Provision for Income Taxes
Net Income After Taxes	168	114	37.4	92	-11.7
Minority Interest
Net Income Before Extraordinary Items
Net Income	168	114	37.3	96.1	-9.27
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	168	114	37.3	96.1	-9.27
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.4	0.907	-0.382	0.832	-0.174
Dividends per Share